Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up – Here’s What Happened

Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) gapped up prior to trading on Thursday . The stock had previously closed at $8.79, but opened at $9.6150. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.66, with a volume of 1,572 shares changing hands.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SGIOY. The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research note on Wednesday, April 8th. Zacks Research lowered shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong sell” rating in a research report on Thursday, April 16th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Up 3.6%

The business has a 50 day simple moving average of $10.47 and a two-hundred day simple moving average of $9.78. The company has a current ratio of 5.84, a quick ratio of 5.21 and a debt-to-equity ratio of 0.01. The company has a market cap of $16.49 billion, a PE ratio of 12.11, a price-to-earnings-growth ratio of 0.65 and a beta of 0.10.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.18 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.03. The business had revenue of $881.71 million during the quarter, compared to the consensus estimate of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 14.09% and a net margin of 41.08%. On average, analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.78 EPS for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.